AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23689475 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention with higher population coverage (1 per 309 population)
Number of subjects: 19301
Study 23689475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19301
Study 22032742 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (DTMS) at 20 Hz, 5 days a week for 4 weeks
Number of subjects: 54
Study 22032742 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (DTMS)
Number of subjects: 54
Study 19531521 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (BM) 12 mg
Number of subjects: 259
Study 19531521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 17915499 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-administered cognitive enhancement program (COGENT) throughout the school year
Number of subjects: 45
Study 17915499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive enhancement program (COGENT) for the first half of the year followed by pull‐out cognitive‐based reading enhancement program (PREP)
Number of subjects: 45
Study 17915499 — intervention group
Group type: COMPARATOR
Intervention: No‐risk control group
Number of subjects: 45
Study 15518095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg with dexamethasone 8 mg (group OD)
Number of subjects: 100
Study 15518095 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg (group O)
Number of subjects: 100
Study 11529645 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sclerosis patients
Number of subjects: 31
Study 11529645 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal patients and controls
Number of subjects: 31
Study 11529645 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal patients and controls
Number of subjects: 31
Study 9764038 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 0
Study 9764038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8628585 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation training
Number of subjects: 48
Study 8628585 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 48
Study 8628585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined approach
Number of subjects: 48
Study 8628585 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 48
Study 3234635 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg three times daily for 3 days
Number of subjects: 15
Study 1139193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol (0.2, 0.1, and 0.05 mug kg‐minus1 min‐minus1)
Number of subjects: 5
Study 1139193 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.1, 0.5, and 0.025 mug kg‐minus1 min‐minus1)
Number of subjects: 5
Study 31902736 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 74
Study 31902736 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 74
Study 31496659 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiopronin (15 mg/kg, 24 hrs)
Number of subjects: 0
Study 31496659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (792 mg/kg, 24 hrs)
Number of subjects: 0
Study 31496659 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 0
Study 31496659 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation fluid volume requirement
Number of subjects: 0
Study 28575389 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin + 250 mg relebactam
Number of subjects: 298
Study 28575389 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin + 125 mg relebactam
Number of subjects: 298
Study 28575389 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin alone
Number of subjects: 298
Study 28575389 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including imipenem non-susceptible pathogens)
Number of subjects: 298
Study 28575389 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (treatment-emergent adverse events)
Number of subjects: 298
Study 25963104 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial (60 min of continuous moderate-high intensity treadmill running)
Number of subjects: 15
Study 25963104 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 15
Study 25963104 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial
Number of subjects: 15
Study 25963104 — intervention group
Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 15
Study 24197719 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion intervention (n = 29)
Number of subjects: 51
Study 24197719 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n = 22)
Number of subjects: 51
Study 21968856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic Intervention Treatment (DIT)
Number of subjects: 68
Study 19489504 — intervention group
Group type: EXPERIMENTAL
Intervention: Hwato never and muscle stimulator
Number of subjects: 87
Study 19489504 — intervention group
Group type: COMPARATOR
Intervention: G 6805 electronic stimulator
Number of subjects: 87
Study 17406651 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care (MBC) approach with citalopram as the first treatment step
Number of subjects: 0
Study 17406651 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care (MBC) approach
Number of subjects: 0
Study 14729745 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg every 12 h (n = 215)
Number of subjects: 430
Study 14729745 — intervention group
Group type: COMPARATOR
Intervention: Teicoplanin (n = 215)
Number of subjects: 430
Study 11706534 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward bending posture
Number of subjects: 44
Study 11706534 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated work posture
Number of subjects: 44
Study 11706534 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived exertion
Number of subjects: 44
Study 11706534 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 44
Study 9204512 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 50
Study 9204512 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 50
Study 7967317 — intervention group
Group type: EXPERIMENTAL
Intervention: SM (streptomycin) twice weekly for 6 months in addition to INH and RFP for 9 months (S2 group)
Number of subjects: 212
Study 7967317 — intervention group
Group type: COMPARATOR
Intervention: EB (ethambutol) for 6 months in addition to INH and RFP for 9 months (E group)
Number of subjects: 212
Study 3337792 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 3337792 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 30
Study 30821827 — intervention group
Group type: COMPARATOR
Intervention: 3 negative screens
Number of subjects: 22229
Study 30821827 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 positive screens with last negative or 2 negative screens with last positive
Number of subjects: 22229
Study 30821827 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or more screens positive with last positive
Number of subjects: 22229
Study 30821827 — intervention group
Group type: EXPERIMENTAL
Intervention: PLCO2012results (model including PLCOm2012 scores and screening results)
Number of subjects: 22229
Study 30821827 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial negative scans with elevated PLCOm2012 six-year risks of at least 2.6%
Number of subjects: 22229
Study 28294373 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Number of subjects: 8000
Study 28294373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study 25515276 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Position Trainer (SPT)
Number of subjects: 55
Study 25515276 — intervention group
Group type: COMPARATOR
Intervention: Tennis Ball Technique (TBT)
Number of subjects: 55
Study 23510568 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Light Roast (MLR) coffee
Number of subjects: 20
Study 23510568 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Roast (MR) coffee
Number of subjects: 20
Study 21158908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 101
Study 21158908 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg alone
Number of subjects: 101
Study 21158908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day plus Melatonin 3 mg
Number of subjects: 101
Study 21158908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day plus Melatonin 5 mg
Number of subjects: 101
Study 21158908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 18469238 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose meal
Number of subjects: 10
Study 18469238 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread meal
Number of subjects: 10
Study 18469238 — intervention group
Group type: COMPARATOR
Intervention: Pasta meal
Number of subjects: 10
Study 17880560 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous histamine (1-10 ng twice a week; n = 46)
Number of subjects: 92
Study 17880560 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium valproate (500 mg daily dose; n = 46)
Number of subjects: 92
Study 14764889 — intervention group
Group type: EXPERIMENTAL
Intervention: mannitol‐LBG
Number of subjects: 60
Study 14764889 — intervention group
Group type: COMPARATOR
Intervention: barium
Number of subjects: 60
Study 14764889 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 60
Study 11723270 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush-evoked allodynia
Number of subjects: 8
Study 11723270 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin pain alone
Number of subjects: 8
Study 9206908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative cholangiography
Number of subjects: 100
Study 7962392 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with endometriosis
Number of subjects: 50
Study 7962392 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal fluid from matched controls
Number of subjects: 50
Study 7962392 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with mild endometriosis
Number of subjects: 50
Study 7962392 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal fluid from patients with severe endometriosis
Number of subjects: 50
Study 3631681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 95
Study 3631681 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown recluse spider antivenom
Number of subjects: 95
Study 3631681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dapsone and antivenom)
Number of subjects: 95
Study 3631681 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (given to all patients)
Number of subjects: 95
Study 3631681 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical data)
Number of subjects: 95
Study 30680975 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (LABA-LAMA-ICS) - vilanterol 25 µg/umeclidinium 62.5 µg/fluticasone furoate 100 µg
Number of subjects: 0
Study 30680975 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (LABA-ICS or LABA-LAMA)
Number of subjects: 0
Study 28261978 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ Shot 2™
Number of subjects: 109
Study 28261978 — intervention group
Group type: EXPERIMENTAL
Intervention: Procore®
Number of subjects: 109
Study 28261978 — intervention group
Group type: EXPERIMENTAL
Intervention: Expect™
Number of subjects: 109
Study 28261978 — intervention group
Group type: COMPARATOR
Intervention: All needles
Number of subjects: 109
Study 25635984 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (120 subjects)
Number of subjects: 262
Study 25635984 — intervention group
Group type: COMPARATOR
Intervention: Non-obese group (142 subjects)
Number of subjects: 262
Study 24950218 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitor displaying feedback about steps and energy consumed
Number of subjects: 104
Study 24950218 — intervention group
Group type: COMPARATOR
Intervention: Blinded monitor (control)
Number of subjects: 104
Study 24950218 — intervention group
Group type: EXPERIMENTAL
Intervention: Team competition (Phase 2)
Number of subjects: 104
Study 24950218 — intervention group
Group type: COMPARATOR
Intervention: Team competition (Control)
Number of subjects: 104
Study 24950218 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (Phase 2)
Number of subjects: 104
Study 20685168 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient focused music (audio pillow)
Number of subjects: 98
Study 20685168 — intervention group
Group type: EXPERIMENTAL
Intervention: Loudspeaker music
Number of subjects: 98
Study 20685168 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual sound environment)
Number of subjects: 98
Study 19589164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment for malaria (IPTp) using sulfadoxine-pyrimethamine (SP)
Number of subjects: 209
Study 17224353 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional bone setting
Number of subjects: 61
Study 17224353 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 61
Study 15310785 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 30
Study 15310785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11173314 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 317
Study 11173314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 11173314 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 317
Study 11173314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 317
Study 9576446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.i.d.
Number of subjects: 398
Study 9576446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 7932892 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing diet (n = 51)
Number of subjects: 98
Study 7932892 — intervention group
Group type: COMPARATOR
Intervention: Standard stress enteral formula (n = 47)
Number of subjects: 98
Study 3652696 — intervention group
Group type: EXPERIMENTAL
Intervention: Food additives (preservatives and food colorings)
Number of subjects: 101
Study 3652696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 30632425 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3-Butanediol (BD)
Number of subjects: 9
Study 30632425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28356091 — intervention group
Group type: EXPERIMENTAL
Intervention: Kundalini yoga
Number of subjects: 159
Study 28356091 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 159
Study 28356091 — intervention group
Group type: COMPARATOR
Intervention: Evidence-based advice
Number of subjects: 159
Study 26474679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol 500/20 μg b.i.d.
Number of subjects: 309
Study 26474679 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/formoterol 100/10 μg b.i.d.
Number of subjects: 309
Study 23361929 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited medial parapatellar (MPP) approach
Number of subjects: 60
Study 23361929 — intervention group
Group type: COMPARATOR
Intervention: Mini-midvastus (MV) approach
Number of subjects: 60
Study 21310551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 20mg twice a day
Number of subjects: 156
Study 21310551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 18493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Medical Appointment (SMA)
Number of subjects: 0
Study 18493699 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 0
Study 18493699 — intervention group
Group type: EXPERIMENTAL
Intervention: Process redesign intervention (proactive contact)
Number of subjects: 0
Study 17581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process quality
Number of subjects: 114
Study 17581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' self-perception of knowledge
Number of subjects: 114
Study 17581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trial satisfaction
Number of subjects: 114
Study 17581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between knowledge and satisfaction
Number of subjects: 114
Study 17581796 — intervention group
Group type: EXPERIMENTAL
Intervention: Age association with knowledge level
Number of subjects: 114
Study 12755528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol 50 microg every 4 h
Number of subjects: 106
Study 12755528 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol 50 microg every 4 h
Number of subjects: 106
Study 12755528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 10868559 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg/NGM 90 microg
Number of subjects: 221
Study 10868559 — intervention group
Group type: COMPARATOR
Intervention: E2/NETA 1 mg
Number of subjects: 221
Study 9188961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramaflex brackets (TP Orthodontics Inc, LaPorte, Ind)
Number of subjects: 40
Study 9188961 — intervention group
Group type: COMPARATOR
Intervention: Transcend 6000 brackets (Unitek Corp, Monrovia, Calif)
Number of subjects: 40
Study 1300519 — intervention group
Group type: EXPERIMENTAL
Intervention: Advent (fluoropolymer) lens
Number of subjects: 6
Study 1300519 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft lens (Bausch & Lomb U4)
Number of subjects: 6
Study 1300519 — intervention group
Group type: COMPARATOR
Intervention: Polymethyl methacrylate (PMMA), silicone acrylate, and fluorosilicone acrylate lenses
Number of subjects: 6
Study 1300519 — intervention group
Group type: COMPARATOR
Intervention: Rigid lenses
Number of subjects: 6
Study 1300519 — intervention group
Group type: COMPARATOR
Intervention: Rigid lenses (excluding Advent)
Number of subjects: 6
Study 3745524 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% anthralin with 2% salicylic acid in petrolatum
Number of subjects: 15
Study 3745524 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing concentrations of anthralin (0.3%, 1%, 3%) with 2% salicylic acid in petrolatum
Number of subjects: 15
Study 3745524 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing concentrations of anthralin (0.3%, 1%, 3%) for patients who failed to respond to UVB therapy
Number of subjects: 15
Study 3745524 — intervention group
Group type: COMPARATOR
Intervention: 2% salicylic acid in petrolatum alone
Number of subjects: 15
Study 31696762 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 486
Study 31696762 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 486
Study 31696762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BP-SES and DP-EES
Number of subjects: 486
Study 30400117 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training for 6 weeks
Number of subjects: 40
Study 30400117 — intervention group
Group type: COMPARATOR
Intervention: Home-based traditional balance exercises
Number of subjects: 40
Study 26954876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dyclonine hydrochloride mucilage (ODHM)
Number of subjects: 932
Study 26954876 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine spray (TS)
Number of subjects: 932
Study 25019119 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment with occlusal splint and analgesic and muscle relaxant medication (Group A)
Number of subjects: 70
Study 25019119 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive prosthodontic procedures (Group B)
Number of subjects: 70
Study 25019119 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) - patients who refused treatment
Number of subjects: 70
Study 22238631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense cranial electroacupuncture stimulation (DCEAS)
Number of subjects: 73
Study 22238631 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive electroacupuncture (n‐EA)
Number of subjects: 73
Study 20714820 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal contact Internet-based diabetes self-management program
Number of subjects: 463
Study 20714820 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate contact Internet-based diabetes self-management program
Number of subjects: 463
Study 20714820 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 463
Study 18508951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 25 mg bid
Number of subjects: 13
Study 18508951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 50 mg bid
Number of subjects: 13
Study 18508951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 75 mg bid
Number of subjects: 13
Study 18508951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 75 mg tid
Number of subjects: 13
Study 18508951 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 100 mg dose
Number of subjects: 13
Study 18508951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin with high-fat meal
Number of subjects: 13
Study 18508951 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 50 to 225 mg/day
Number of subjects: 13
Study 15910012 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg before MDMA 100 mg
Number of subjects: 7
Study 15910012 — intervention group
Group type: COMPARATOR
Intervention: Placebo before MDMA 100 mg
Number of subjects: 7
Study 12870566 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg b.d.)
Number of subjects: 20